Onsior 10 mg Tablets for Dogs

In clinical studies in dogs with osteoarthritis, inadequate response to
treatment was seen in 10–15% of the dogs.

i). Special precautions for use in animals
The safety of the veterinary medicinal product has not been established in
dogs weighing less than 2.5 kg or under 3 months of age.
For long term therapy, liver enzymes should be monitored at the start of
therapy, e.g. after 2, 4 and 8 weeks. Thereafter it is recommended to
continue regular monitoring, e.g. every 3–6 months. Therapy should be
discontinued if liver enzyme activities increase markedly or the dog shows
clinical signs such as anorexia, apathy or vomiting in combination with
elevated liver enzymes.
Use in dogs with impaired cardiac or renal function or dogs that are
dehydrated, hypovolaemic or hypotensive may involve additional risks. If use
cannot be avoided, these dogs require careful monitoring.
Use this product under strict veterinary monitoring in dogs with a risk of
gastrointestinal ulcers, or if the dog previously displayed intolerance to other
NSAIDs.
ii). Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Wash hands after use of the veterinary medicinal product.

Issued: October 2023
AN: 02941/2022
In case of accidental ingestion, seek medical advice immediately and show
the package leaflet or the label to the physician. In small children, accidental
ingestion increases the risk for NSAID adverse effects.
For pregnant women, particularly near-term pregnant women, prolonged
dermal exposure increases the risk of premature closure of the ductus
arteriosus in the foetus.
Special precautions for the protection of the environment:
Not applicable.
iii). Other precautions
Not applicable.